Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: Macrophage-targeted steroid therapy

International Journal of Hematology

Volumn 95, Issue 4, 2012, Pages 428-433

  Nishiwaki, Satoshi ^a,b,c   Saito, Shigeki ^a   Goto, Tatsunori ^c   Miyamura, Koichi ^c   Nakayama, Takayuki ^a   Kato, Tomonori ^a   Koyama, Daisuke ^c   Murata, Makoto ^a   Mizuno, Hiroki ^a   Yokohata, Emi ^c   Matsumoto, Kimikazu ^c   Nishida, Tetsuya ^a   Imahashi, Nobuhiko ^a,c   Kubota, Naomi ^c   Ito, Masafumi ^c   Sugimoto, Kyoko ^a   Seto, Aika ^c   Ozawa, Yukiyasu ^c   Kamoshita, Sonoko ^c   Naoe, Tomoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b THE JAPANESE SOCIETY OF GASTROENTEROLOGICAL SURGERY   (Japan)

^c JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

Allogeneic stem cell transplantation; Dexamethasone palmitate; Engraftment failure; Hemophagocytic syndrome; Macrophages

Indexed keywords

DEXAMETHASONE 21 PALMITATE; DEXAMETHASONE DERIVATIVE; DEXAMETHASONE SODIUM PHOSPHATE; UNCLASSIFIED DRUG;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CASE REPORT; CELL VIABILITY; DRUG EFFICACY; DRUG TARGETING; FEMALE; GRAFT FAILURE; HEMOPHAGOCYTIC SYNDROME; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; STEROID THERAPY;

ADULT; CELL SURVIVAL; CELLS, CULTURED; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGES; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84862885421     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1023-z     Document Type: Article

References (14)

1. Takagi S, Masuoka K, Uchida N, et al. High incidence of haemophagocytic syndrome following umbilical cord blood transplantation for adults. Br J Haematol. 2009;147:543-53.
2. Sindrilaru A, Peters T, Wieschalka S, et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest. 2011; 121:985-97.
3. Imahashi N, Inamoto Y, Ito M, et al. Clinical significance of hemophagocytosis in BM clot sections during the peri-engraftment period following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011 (in press).
4. Koyama M, Sawada A, Yasui M, et al. Encouraging results of low-dose etoposide in the treatment of early-onset hemophagocytic syndrome following allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2007;86:466-7.
5. Fukunaga A, Nakamura F, Yoshinaga N, et al. Successful treatment with combined chemotherapy of two adult cases of hemophagocytic lymphohistiocytosis in recipients of umbilical cord blood cell transplantation. Int J Hematol. 2011;93:551-4.
6. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976;84:304-15.
7. Fukuno K, Tsurumi H, Yamada T, et al. Graft failure due to hemophagocytic syndrome after autologous peripheral blood stem cell transplantation. Int J Hematol. 2001;73:262-5.
8. Muller M, Renkawitz R. The glucocorticoid receptor. Biochim Biophys Acta. 1088;1991:171-82.
9. Pak CC, Fidler IJ. Liposomal delivery of biological response modifiers to macrophages. Biotherapy. 1991;3:55-64.
10. Martinez FO, Gordon S, Locati M, et al. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177:7303-11.
11. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-86.
12. Sayer HG, Longton G, Bowden R, et al. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood. 1994;84:1328-32.
13. Inamoto Y, Ito M, Suzuki R, et al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transplant. 2009;44:43-9.
14. Camps IR. Risk factors for invasive fungal infections in haematopoietic stem cell transplantation. Int J Antimicrob Agents. 2008;32(SUPPL. 2):S119-23.